GlassScriptPhysician profile
Jonathan Thomas Cobb
NPI 1700489697
$1,757.94
in general payments reported to CMS, 2019-2025
15 companies · $866 in 2025
The $866 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $892 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $516.21 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $240.59 | 2024-2025 | Airsupra, Breztri |
| Pfizer INC. | $207.72 | 2024-2025 | |
| Novo Nordisk INC | $156.98 | 2024-2025 | Ozempic, Rybelsus |
| Amgen INC. | $148.71 | 2024-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $119.13 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $73.80 | 2024-2025 | Korlym |
| Lilly USA, LLC | $70.02 | 2024 | Mounjaro, Jardiance, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.52 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $51.02 | 2024 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $35.45 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $34.03 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.31 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $16.58 | 2024 | |
| Novartis Pharmaceuticals Corporation | $14.87 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.